{"id":"NCT00628108","sponsor":"UCB Pharma","briefTitle":"Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2008-03-04","resultsPosted":"2009-10-14","lastUpdate":"2015-03-06"},"enrollment":69,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Rhinitis","Chronic Urticaria"],"interventions":[{"type":"DRUG","name":"Levocetirizine 1.25 mg","otherNames":["Xyzal"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Levocetirizine","type":"EXPERIMENTAL"}],"summary":"To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.","primaryOutcome":{"measure":"Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Ventricular Rate (VR)","timeFrame":"Baseline, 14 days","effectByArm":[{"arm":"Placebo","deltaMin":-7.6,"sd":17.3},{"arm":"Levocetirizine","deltaMin":-4,"sd":16.9}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":13},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":["20819318"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Pyrexia","Diarrhoea","Constipation","Irritability","Otitis media"]}}